News

The document further reveals that Ge Ming Pharmaceutical has also requested Erasca to cease all comparative statements involving Eras-0015 and other drugs. This legal demand highlights a potential intellectual property conflict between the two companies in the field of tumor treatment. Currently, Erasca has not made a public response regarding this matter. The market is closely watching how this dispute may impact the progress of drug development for both parties and their performance in the capital markets.

This development marks a critical step forward in the clinical application of this experimental therapy for specific patient groups.

The UK Financial Conduct Authority launched a consultation on Monday, proposing to remove the seven-day interval between a transaction announcement and the start of marketing by investment banks, thereby shortening the public phase of IPOs. The authority is also reviewing rules that require companies to provide independent analysts with the same information as transaction parties. These proposals would overturn rules introduced in 2018, which aimed to bring in external research and offer investors a more independent perspective, but also made London IPOs more susceptible to market sentiment before completion. Regulatory director Jon Relleen stated: "Market feedback shows these rules have not delivered the expected benefits and have instead increased risk, cost, and complexity." The consultation will run until May 29.